Prevention of Graft-Versus-Host Disease (GVHD) after Haploidentical Hematopoietic Stem Cell Transplantation
Conditions
Interventions
Tocilizumab group:None
Control Group:None
Sponsors
Beijing Gaobo Boren Hospital
Eligibility
Sex/Gender
All
Age
6 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Age between 6 and 65 years old; 2. Patients who underwent haploidentical allogeneic hematopoietic stem cell transplantation in our hospital between January 1, 2021 and December 31, 2023; 3. An ECOG performance status score of <=2; 4. Complete clinical data related to the key study endpoints.
Exclusion criteria
Exclusion criteria: 1.Incomplete or missing medical records; 2.History of other malignancies within the past 5 years (except for adequately treated cervical carcinoma in situ, squamous cell carcinoma of the skin, or controlled basal cell carcinoma of the skin); 3.Any other reason that the investigator deems the subject unsuitable for participation in this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Graft-Related Failure-Free Survival (GRFS);Incidence of acute GVHD;Incidence rate of chronic graft-versus-host disease (chronic GVHD);Overall survival;Event-Free Survival, EFS; | — |
Secondary
| Measure | Time frame |
|---|---|
| Infection Incidence Rate;Treatment-Related Mortality;Treatment-Related Mortality;Neutrophil Engraftment Rate (NER);Relapse Rate, RR;Platelet Engraftment Rate; | — |
Countries
China
Contacts
Public ContactLi Zhihui
Beijing Gaobo Boren Hospital
Outcome results
None listed